Portal de Periódicos da CAPES

Four Cases with FUS/CHOP Fusion Gene Products Positive Myxoid Liposarcoma Responding Effectively to Trabectedin Monotherapy

2024; Dove Medical Press; Volume: Volume 17; Linguagem: Inglês

10.2147/ott.s486163

1178-6930

Hirohito Kirishi, Hiromichi Yamane, Nobuaki Ochi, Yoshihide Sunada, Ayaka Mimura, Yoko Kosaka, Naruhiko Ichiyama, Tatsuyuki Kawahara, Yasunari Nagasaki, Hidekazu Nakanishi, Toshiyuki Kunisada, Nagio Takigawa,

Cardiac tumors and thrombi

Myxoid liposarcoma, a rare type of tumor, accounts for approximately 30% of all liposarcomas. Myxoid liposarcomas harboring the FUS/CHOP fusion gene have shown promising results with trabectedin in basic research and some clinical experiments. However, the efficacy and safety of trabectedin in chemotherapy-naive soft tissue sarcomas or FUS/CHOP fusion gene-positive myxoid liposarcomas have not yet been established. Therefore, we evaluated the effectiveness and safety of trabectedin monotherapy in four cases of myxoid liposarcoma harboring the FUS/CHOP fusion gene at our hospital.